{"id":69013,"date":"2026-03-13T11:58:53","date_gmt":"2026-03-13T11:58:53","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=69013"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"kpv-lysine-proline-valine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/kpv-lysine-proline-valine\/","title":{"rendered":"KPV (Lizin-Prolin-Valin)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Gyors v\u00e1lasz \u2013 Mi az a KPV?<\/h3>\n<p style=\"margin: 0;\"><strong>KPV<\/strong> a Lys-Pro-Val tripeptid \u2013 az alfa-melanocit-stimul\u00e1l\u00f3 hormon (\u03b1-MSH) C-termin\u00e1lis gyullad\u00e1scs\u00f6kkent\u0151 fragmentuma. A sz\u00e9lesebb spektrum\u00fa melanokortin anal\u00f3gokkal ellent\u00e9tben a KPV-nek <strong>nincs pigment\u00e1ci\u00f3s hat\u00e1sa<\/strong>; kutat\u00e1si jelz\u00e9se kiz\u00e1r\u00f3lag gyullad\u00e1scs\u00f6kkent\u0151, NFkB-g\u00e1tl\u00e1son \u00e9s masztsejt-stabiliz\u00e1ci\u00f3n kereszt\u00fcl. Vizsg\u00e1lt\u00e1k IBD, allergi\u00e1s gyullad\u00e1s \u00e9s b\u0151rgyullad\u00e1s kutat\u00e1s\u00e1ban. Csak laborat\u00f3riumi kutat\u00e1si c\u00e9lra szolg\u00e1l\u00f3 liofiliz\u00e1lt ampull\u00e1kban kaphat\u00f3 5 mg \u00e9s 10 mg koncentr\u00e1ci\u00f3ban.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Mit kapsz a MedsBase-n\u00e1l:<\/strong> Kutat\u00e1si min\u0151s\u00e9g\u0171 liofiliz\u00e1lt peptidok \u00b7 HPLC \u226599% tisztas\u00e1g (tan\u00fas\u00edtv\u00e1ny k\u00e9r\u00e9sre) \u00b7 Diszkr\u00e9t, h\u0151m\u00e9rs\u00e9klet-stabil csomagol\u00e1s \u00b7 Vil\u00e1gszerte peptid fut\u00e1rszolg\u00e1lat \u00b7 1,400+ hiteles\u00edtett <a href=\"https:\/\/medsbase.com\/hu\/reviews\/\">v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Minden rendel\u00e9st fedez a <a href=\"https:\/\/medsbase.com\/hu\/medsbase-re-shipment-assurance-policy\/\"><strong>\u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifik\u00e1ci\u00f3<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">R\u00e9szlet<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS sz\u00e1m<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">67727-97-3<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekul\u00e1ris k\u00e9plet<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>16<\/sub>H<sub>30<\/sub>N<sub>4<\/sub>O<sub>4<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulat\u00f6meg<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">342.43 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Szekvencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lys-Pro-Val (\u03b1-MSH 11\u201313)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofiliz\u00e1lt por (vagy a sz\u00e1ll\u00edtott form\u00e1ban)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tisztas\u00e1g<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-vel ellen\u0151rizve, COA ig\u00e9ny szerint)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>T\u00e1rol\u00e1s<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofiliz\u00e1lt: 2\u20138 \u00b0C (h\u0171t\u0151szekr\u00e9ny) munkak\u00e9szletk\u00e9nt; \u221220 \u00b0C hossz\u00fa t\u00e1v\u00fa t\u00e1rol\u00e1sra lez\u00e1ratlan \u00fcvegek eset\u00e9n. Rekonstitu\u00e1lt: 2\u20138 \u00b0C, haszn\u00e1lat ~30 napon bel\u00fcl. V\u00e9dj\u00fck a f\u00e9nyt\u0151l. Ne fagyassza-v\u00e1lassza fel az \u00fajra\u00e1ll\u00edtott oldatot.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Oldhat\u00f3s\u00e1g<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakt\u00e9riumstatikus v\u00edz (aj\u00e1nlott) vagy steril v\u00edz r\u00f6videbb haszn\u00e1latra<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Kutat\u00e1si c\u00e9lra<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Csak laborat\u00f3riumi kutat\u00e1si c\u00e9lra. Nem haszn\u00e1lhat\u00f3 hum\u00e1n vagy \u00e1llatgy\u00f3gy\u00e1szati diagnosztikai vagy ter\u00e1pi\u00e1s c\u00e9lra.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mi az a KPV?<\/h2>\n<p><strong>KPV<\/strong> a h\u00e1rombet\u0171s egybet\u0171s k\u00f3d r\u00f6vid\u00edt\u00e9se a <strong>Lys-Pro-Val tripeptidnek<\/strong> \u2013 az alfa-melanocit-stimul\u00e1l\u00f3 hormon (\u03b1-MSH) C-termin\u00e1lis h\u00e1rom aminosavj\u00e1nak (11\u201313. poz\u00edci\u00f3). Az 1980\u20131990-es \u00e9vekben t\u00f6bb kutat\u00f3csoport is \u00e9szrevette, hogy a teljes \u03b1-MSH molekula k\u00e9t funkcion\u00e1lisan elk\u00fcl\u00f6n\u00edthet\u0151 hat\u00e1st produk\u00e1l: a j\u00f3l ismert N-termin\u00e1lis MC-receptor pigment\u00e1ci\u00f3s\/aktiv\u00e1l\u00f3 hat\u00e1st, \u00e9s egy C-termin\u00e1lis <strong>gyullad\u00e1scs\u00f6kkent\u0151<\/strong> Aktivitas. Ketika fragmen C-terminal KPV tripeptida disintesis dan diuji secara terisolasi, ia mereproduksi efek anti-inflamasi tanpa efek samping pigmentasi.<\/p>\n<p>Berat molekul sekitar 342,4 Da. KPV adalah salah satu peptida terkecil dalam keluarga melanokortin dan salah satu peptida yang paling banyak diteliti dalam penelitian anti-inflamasi. Ini disuplai sebagai bubuk liofilisasi kemurnian tinggi. <strong>laborat\u00f3riumi kutat\u00e1si c\u00e9lra szolg\u00e1l<\/strong> \u00e9s nem sz\u00e1nd\u00e9kozik emberi vagy \u00e1llatgy\u00f3gy\u00e1szati diagn\u00f3zisra vagy ter\u00e1pi\u00e1ra. A mechanizmus, IBD-kutat\u00e1si el\u0151zm\u00e9nyek \u00e9s veremkontextus r\u00e9szletei\u00e9rt l\u00e1togasson el <a href=\"https:\/\/medsbase.com\/hu\/kpv-peptide-anti-inflammatory-guide\/\">Mekanisme Kerja \u2014 Tiga Jalur Anti-Inflamasi<\/a>.<\/p>\n<h2>Hat\u00e1smechanizmus \u2014 H\u00e1rom gyullad\u00e1scs\u00f6kkent\u0151 \u00fatvonal<\/h2>\n<p>\u2014 KPV menghambat translokasi NFkB ke dalam inti, mencegah transkripsi sitokin pro-inflamasi termasuk TNF-alpha, IL-6, IL-1\u03b2, dan IL-8. NFkB adalah regulator utama ekspresi gen inflamasi, sehingga penghambatan aktivasinya menghasilkan efek anti-inflamasi yang luas dan hulu.<\/p>\n<ul>\n<li><strong>Stabilisasi sel mast<\/strong> \u2014 KPV mengurangi degranulasi sel mast dan pelepasan histamin dalam model penelitian. Ini adalah mekanisme yang berbeda dari penghambatan NFkB dan sangat relevan untuk penelitian alerg-inflamasi dan model inflamasi kulit topikal.<\/li>\n<li><strong>Pemisahan peptida-vs-MSH<\/strong> \u2014 A KPV cs\u00f6kkenti a mastsejtek degranul\u00e1ci\u00f3j\u00e1t \u00e9s a hisztaminfelszabadul\u00e1st k\u00eds\u00e9rleti modellekben. Ez elt\u00e9r\u0151 mechanizmus az NFkB g\u00e1tl\u00e1st\u00f3l, \u00e9s k\u00fcl\u00f6n\u00f6sen relev\u00e1ns az allergi\u00e1s gyullad\u00e1s kutat\u00e1s\u00e1ban \u00e9s a topik\u00e1lis b\u0151rgyullad\u00e1si modellekben.<\/li>\n<li><strong>tidak mengaktifkan MC1R<\/strong> \u2014 mivel a KPV csak a C-termin\u00e1lis fragmentum, <strong>Implikasi penelitian praktis: KPV adalah alat penelitian anti-inflamasi yang bersih yang menghasilkan sinyal anti-inflamasi \u03b1-MSH tanpa efek penyamaran, gairah, atau modulasi nafsu makan yang mempersulit interpretasi penelitian menggunakan agonis MC analog panjang penuh.<\/strong> (the pigmentation receptor) or MC4R (the arousal\/feeding receptor). This mechanistically separates the anti-inflammatory activity from \u03b1-MSH\u2019s other effects \u2014 distinct from broader MC analogs such as <a href=\"https:\/\/medsbase.com\/hu\/melanotan-ii\/\">Melanotan II<\/a> vagy <a href=\"https:\/\/medsbase.com\/hu\/pt-141\/\">PT-141<\/a>.<\/li>\n<\/ul>\n<p>The practical research implication: KPV is a \u201cclean\u201d anti-inflammatory research tool that produces the \u03b1-MSH anti-inflammatory signal without the tanning, arousal, or appetite-modulation effects that complicate interpretation of research using full-length MC agonists.<\/p>\n<h2>K\u00f6zz\u00e9tett kutat\u00e1si alkalmaz\u00e1sok<\/h2>\n<p>A KPV-t laborat\u00f3riumi kutat\u00e1si kontextusokban haszn\u00e1lj\u00e1k, amelyek a k\u00f6vetkez\u0151ket vizsg\u00e1lj\u00e1k:<\/p>\n<ul>\n<li><strong>IBD \u00e9s colitis kutat\u00e1s<\/strong> \u2014 gyullad\u00e1sos b\u00e9lbetegs\u00e9g\u0171 r\u00e1gcs\u00e1l\u00f3modellek; a KPV mind SC, mind or\u00e1lis \u00faton akt\u00edv, ami rendk\u00edv\u00fcl rugalmass\u00e1 teszi a GI-gyullad\u00e1s kutat\u00e1s\u00e1ban (Brzoska et al., Endocr Rev 2008)<\/li>\n<li><strong>Allergi\u00e1s gyullad\u00e1s<\/strong> \u2014 masztsejt-stabiliz\u00e1ci\u00f3 \u00e9s hisztaminfelszabadul\u00e1s kutat\u00e1sa allergi\u00e1s \u00e9s atopi\u00e1s modellekben<\/li>\n<li><strong>B\u0151rgyullad\u00e1s<\/strong> \u2014 ekc\u00e9ma, pszori\u00e1zis \u00e9s kontakt dermatitis kutat\u00e1si modellek; topik\u00e1lis formul\u00e1ci\u00f3k el\u0151fordulnak egyes kutat\u00e1si protokollokban<\/li>\n<li><strong>Sebgy\u00f3gyul\u00e1s<\/strong> \u2014 a gy\u00f3gyul\u00e1si folyamat gyullad\u00e1sg\u00e1tl\u00f3 szakasz\u00e1nak kutat\u00e1sa, gyakran kombin\u00e1lva <a href=\"https:\/\/medsbase.com\/hu\/bpc-157\/\">BPC-157<\/a> kombin\u00e1lt gyullad\u00e1sg\u00e1tl\u00f3 \u00e9s n\u00f6veked\u00e9si faktor hat\u00e1s \u00e9rdek\u00e9ben<\/li>\n<li><strong>\u00cdz\u00fcleti gyullad\u00e1s<\/strong> \u2014 arthritis \u00e9s \u00edz\u00fcleti gyullad\u00e1s r\u00e1gcs\u00e1l\u00f3 kutat\u00e1si modellek<\/li>\n<li><strong>Stacking kutat\u00e1s<\/strong> \u2014 gyakran p\u00e1ros\u00edtva <a href=\"https:\/\/medsbase.com\/hu\/bpc-157\/\">BPC-157<\/a> a GI \u00e9s k\u00f6t\u0151sz\u00f6veti kutat\u00e1sban, ahol gyullad\u00e1sg\u00e1tl\u00f3 \u00e9s sz\u00f6vetjav\u00edt\u00f3 hat\u00e1sra van sz\u00fcks\u00e9g<\/li>\n<li><strong>Melanokortin \u00f6sszehasonl\u00edt\u00f3 kutat\u00e1s<\/strong> \u2014 egym\u00e1s mellett <a href=\"https:\/\/medsbase.com\/hu\/melanotan-ii\/\">Melanotan II<\/a> \u00e9s <a href=\"https:\/\/medsbase.com\/hu\/pt-141\/\">PT-141<\/a> a tiszta gyullad\u00e1sg\u00e1tl\u00f3 vs MC-receptor hat\u00e1sok elk\u00fcl\u00f6n\u00edt\u00e9s\u00e9re<\/li>\n<\/ul>\n<p>A gyullad\u00e1sg\u00e1tl\u00f3 \u00e9s gy\u00f3gy\u00edt\u00f3 peptidek sz\u00e9lesebb kontextus\u00e1hoz l\u00e1sd a <a href=\"https:\/\/medsbase.com\/hu\/peptides\/\">kutat\u00e1si peptidek katal\u00f3gust<\/a>.<\/p>\n<h2>El\u00e9rhet\u0151 er\u0151ss\u00e9gek \u00e9s koncentr\u00e1ci\u00f3k<\/h2>\n<p>A MedsBase KPV-t az al\u00e1bbi liofiliz\u00e1lt ampulla m\u00e9retekben k\u00edn\u00e1lja:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Ampulla er\u0151ss\u00e9ge<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tipikus felhaszn\u00e1l\u00e1si ter\u00fclet<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Csomagm\u00e9ret<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">R\u00f6vid kutat\u00e1si protokollok, pr\u00f3ba adagol\u00e1s \u2014 kb. 10 alkalomra elegend\u0151 500 mcg adaggal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 vagy 30 ampulla<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard kutat\u00e1si er\u0151ss\u00e9g \u2014 kb. 20 alkalomra elegend\u0151 500 mcg adaggal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 vagy 30 ampulla<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A KPV kutat\u00e1si protokolljai a modellrendszert\u0151l f\u00fcgg\u0151en v\u00e1ltozatosak lehetnek \u2014 200\u2013500 mcg SC napi adagol\u00e1s sziszt\u00e9m\u00e1s gyullad\u00e1sg\u00e1tl\u00f3 kutat\u00e1sokhoz, vagy topik\u00e1lis\/sz\u00e1jon \u00e1t t\u00f6rt\u00e9n\u0151 alkalmaz\u00e1s GI \u00e9s b\u0151rrel kapcsolatos kutat\u00e1si kontextusokban. Minden er\u0151ss\u00e9g\u0171 term\u00e9k liofiliz\u00e1lt por form\u00e1j\u00e1ban ker\u00fcl sz\u00e1ll\u00edt\u00e1sra, 99%+-os HPLC tisztas\u00e1ggal.<\/p>\n<h2>\u00d6sszehasonl\u00edt\u00e1s \u2014 KPV vs egy\u00e9b gyullad\u00e1sg\u00e1tl\u00f3\/melanokortin peptidek<\/h2>\n<p>A KPV az egyik legtiszt\u00e1bb gyullad\u00e1sg\u00e1tl\u00f3 peptid a kutat\u00e1si felhaszn\u00e1l\u00e1sban, mivel hat\u00e1sa rendk\u00edv\u00fcl specifikus. Kapcsol\u00f3d\u00f3 vegy\u00fcletekkel \u00f6sszehasonl\u00edtva:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">KPV<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Melanotan II<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Hossz<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 aminosav<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 aminosav<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">7 aminosav (ciklikus)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Els\u0151dleges hat\u00e1s<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kiz\u00e1r\u00f3lag gyullad\u00e1sg\u00e1tl\u00f3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Gyullad\u00e1scs\u00f6kkent\u0151 + sz\u00f6vetregener\u00e1ci\u00f3 + GH-receptor<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sz\u00e9les spektrum\u00fa MC-agonist\u00e1k (MC1-5)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>MC-receptor aktivit\u00e1s<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nincs (csak C-termin\u00e1lis r\u00e9sz)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nincs<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">MC1, MC3, MC4, MC5<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Pigment\u00e1ci\u00f3ra gyakorolt hat\u00e1s<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nincs<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nincs<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Er\u0151s (els\u0151dleges jelz\u00e9s)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Kutat\u00e1si alkalmaz\u00e1sok<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBD, allergia, b\u0151rgyullad\u00e1s<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00cdn, b\u00e9l, izomregener\u00e1ci\u00f3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Melanogenezis, fotoprotekci\u00f3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A GI gyullad\u00e1s kutat\u00e1s\u00e1ban a KPV + BPC-157 k\u00fcl\u00f6n\u00f6sen gyakori kombin\u00e1ci\u00f3, mivel a KPV fel\u00fcli gyullad\u00e1scs\u00f6kkent\u0151 jelz\u00e9st biztos\u00edt, m\u00edg a BPC-157 sz\u00f6vetregener\u00e1ci\u00f3s n\u00f6veked\u00e9si faktor aktivit\u00e1st. Err\u0151l r\u00e9szletesen \u00edrunk a <a href=\"https:\/\/medsbase.com\/hu\/bpc-157-peptide-healing-recovery-guide\/\">BPC-157 kutat\u00e1si \u00fatmutat\u00f3<\/a>.<\/p>\n<h2>T\u00e1rol\u00e1s \u00e9s rekonstit\u00faci\u00f3<\/h2>\n<p><strong>Rekonstit\u00faci\u00f3 el\u0151tt:<\/strong> a liofiliz\u00e1lt ampull\u00e1kat eredeti csomagol\u00e1sban 2\u20138 \u00b0C-on h\u0171t\u0151ben t\u00e1rolni, ak\u00e1r 36 h\u00f3napig stabil. Ker\u00fclje a por \u00e1llapot\u00fa anyag fagyaszt\u00e1s-olvad\u00e1s ciklusait.<\/p>\n<p><strong>Rekonstit\u00faci\u00f3s elj\u00e1r\u00e1s:<\/strong> Fecskendezze a bakt\u00e9rium\u00f6l\u0151 vizet a peptid flakon oldalfal\u00e1n\u00e1l a fenti t\u00e1bl\u00e1zat szerint. \u00d3vatosan keverje \u2013 ne <strong>nem<\/strong> r\u00e1zza \u2013 \u00e9s v\u00e1rjon 5\u201310 percet a teljes old\u00f3d\u00e1sig. Az oldatnak tiszta \u00e9s sz\u00edntelennek kell lennie.<\/p>\n<p><strong>Rekonstit\u00faci\u00f3 ut\u00e1n:<\/strong> H\u0171t\u0151ben t\u00e1rolja 2\u20138 \u00b0C k\u00f6z\u00f6tt, \u00e9s haszn\u00e1lja fel 30 napon bel\u00fcl. Ne fagyassza az \u00fajrakonstitu\u00e1lt oldatot.<\/p>\n<h2 id=\"faqs\">Gyakran Ism\u00e9telt K\u00e9rd\u00e9sek<\/h2>\n<h3>Mire haszn\u00e1lj\u00e1k a KPV-t a kutat\u00e1sban?<\/h3>\n<p>A KPV-t laborat\u00f3riumi kutat\u00e1sokban haszn\u00e1lj\u00e1k a gyullad\u00e1scs\u00f6kkent\u0151 biol\u00f3gia, gyullad\u00e1sos b\u00e9lbetegs\u00e9gek (IBD) \u00e9s colitis, allergi\u00e1s gyullad\u00e1s, b\u0151rgyullad\u00e1s (ekc\u00e9ma\/pszori\u00e1zis modellek), sebgy\u00f3gyul\u00e1si gyullad\u00e1si f\u00e1zis, \u00edz\u00fcleti gyullad\u00e1s \u00e9s \u00f6sszehasonl\u00edt\u00f3 melanokortin farmakol\u00f3gia vizsg\u00e1lat\u00e1ban. <strong>nem<\/strong> Az FDA \u00e1ltal nem j\u00f3v\u00e1hagyott, \u00e9s itt kiz\u00e1r\u00f3lag laborat\u00f3riumi kutat\u00e1si c\u00e9lra \u00e9rt\u00e9kes\u00edtett.<\/p>\n<h3>Miben k\u00fcl\u00f6nb\u00f6zik a KPV a Melanotan II-t\u0151l vagy a PT-141-t\u0151l?<\/h3>\n<p>A KPV csak az alfa-MSH h\u00e1rom aminosavas C-termin\u00e1lis fragmentuma, m\u00edg a Melanotan II \u00e9s a PT-141 teljes vagy majdnem teljes ciklikus MSH anal\u00f3gok. Ez azt jelenti, hogy a KPV <strong>nincs melanokortin-receptor aktivit\u00e1s<\/strong> \u00e9s ez\u00e9rt nincs pigment\u00e1ci\u00f3 (MC1R), izgalom (MC4R) vagy \u00e9tv\u00e1gy (MC4R) hat\u00e1s \u2014 csak gyullad\u00e1scs\u00f6kkent\u0151 aktivit\u00e1s NFkB \u00e9s mastsejtes \u00fatvonalakon kereszt\u00fcl.<\/p>\n<h3>Mi a tipikus KPV kutat\u00e1si d\u00f3zis?<\/h3>\n<p>A publik\u00e1lt preklinikai protokollok \u00e1ltal\u00e1ban 200\u2013500 mcg subkut\u00e1n napi adagot haszn\u00e1lnak sziszt\u00e9m\u00e1s gyullad\u00e1scs\u00f6kkent\u0151 kutat\u00e1sra. Egyes IBD \u00e9s b\u0151rgyullad\u00e1s kutat\u00e1sokban or\u00e1lis vagy topik\u00e1lis alkalmaz\u00e1st haszn\u00e1lnak. Egy 10 mg-os palack, amelyet 2,0 mL bakteriostatikus v\u00edzzel rekonstitu\u00e1lnak, 5 mg\/mL koncentr\u00e1ci\u00f3t eredm\u00e9nyez \u2014 10 oszt\u00e1s egy U-100 subkut\u00e1n fecskend\u0151n 500 mcg-ot szolg\u00e1ltat.<\/p>\n<h3>J\u00f3v\u00e1hagyta az FDA a KPV-t?<\/h3>\n<p>Nem. A KPV nem kapott FDA, EMA vagy b\u00e1rmilyen szab\u00e1lyoz\u00f3i j\u00f3v\u00e1hagy\u00e1st. A teljes alfa-MSH peptid \u00e9s a KPV-vel kapcsolatos kutat\u00e1s sz\u00e9les k\u00f6rben t\u00e1j\u00e9koztatta a melanokortin gy\u00f3gyszerek fejleszt\u00e9s\u00e9t, de maga a KPV csak kutat\u00e1si c\u00e9lra haszn\u00e1lhat\u00f3. Minden KPV, amelyet a peptid-kutat\u00e1si besz\u00e1ll\u00edt\u00f3k \u00e1rus\u00edtanak, kiz\u00e1r\u00f3lag laborat\u00f3riumi vizsg\u00e1latra szolg\u00e1l.<\/p>\n<h3>Bevehet\u0151 a KPV or\u00e1lisan IBD kutat\u00e1sra?<\/h3>\n<p>Igen. A legt\u00f6bb peptiddel ellent\u00e9tben, amelyeket a gyomorenzimek lebontanak, a KPV meg\u0151rzi egyes gyullad\u00e1scs\u00f6kkent\u0151 hat\u00e1sait az or\u00e1lis \u00faton is publik\u00e1lt IBD \u00e9s colitis kutat\u00e1sokban. Ez rendk\u00edv\u00fcl rugalmass\u00e1 teszi a GI gyullad\u00e1s kutat\u00e1s\u00e1ban, ahol az or\u00e1lis bead\u00e1s k\u00f6zvetlen\u00fcl a GI traktust c\u00e9lozza. A kutat\u00e1si protokollok v\u00e1ltoznak a modellt\u0151l f\u00fcgg\u0151en \u2014 a subkut\u00e1n bead\u00e1s marad a domin\u00e1ns sziszt\u00e9m\u00e1s \u00fatvonal.<\/p>\n<h3>Hogyan kell t\u00e1rolni a KPV-t?<\/h3>\n<p>Liofiliz\u00e1lt palackok: eredeti csomagol\u00e1sban 2\u20138 \u00b0C-on h\u0171tve, ak\u00e1r 36 h\u00f3napig stabil. Rekonstitu\u00e1lt oldat: 2\u20138 \u00b0C-on h\u0171tve, 30 napon bel\u00fcl haszn\u00e1ld fel. Ne fagyaszd a rekonstitu\u00e1lt oldatot.<\/p>\n<h3>Hogyan kell rekonstitu\u00e1lni a KPV-t?<\/h3>\n<p>K\u00f6vesse a fenti \u00fajj\u00e1\u00e1ll\u00edt\u00e1si t\u00e1bl\u00e1zatot. Adjon bakt\u00e9rium\u00f6l\u0151 vizet a flakon oldalfal\u00e1n\u00e1l, \u00f3vatosan keverje, \u00e9s v\u00e1rjon 5\u201310 percet a teljes old\u00f3d\u00e1s \u00e9rdek\u00e9ben. Ne <strong>nem<\/strong> r\u00e1zza.<\/p>\n<h3>\u00d6ssze lehet-e haszn\u00e1lni a KPV-t \u00e9s a BPC-157-et kutat\u00e1sban?<\/h3>\n<p>Igen \u2014 ez az egyik leggyakoribb kutat\u00e1si kombin\u00e1ci\u00f3 a GI \u00e9s k\u00f6t\u0151sz\u00f6veti gyullad\u00e1sra. A KPV fels\u0151bb rend\u0171 NFkB-\u00fatvonal\u00fa gyullad\u00e1scs\u00f6kkent\u0151 jelz\u00e9st biztos\u00edt; <a href=\"https:\/\/medsbase.com\/hu\/bpc-157\/\">BPC-157<\/a> VEGF-\u00fatvonal\u00fa sz\u00f6vetjav\u00edt\u00f3 \u00e9s n\u00f6veked\u00e9si faktor aktivit\u00e1st ny\u00fajt. A mechanizmusok kieg\u00e9sz\u00edt\u0151ek egym\u00e1ssal, nem pedig \u00e1tfed\u0151ek.<\/p>\n<h3>Milyen er\u0151ss\u00e9g\u0171 k\u00e9sz\u00edtm\u00e9nyeket tart k\u00e9szleten a MedsBase?<\/h3>\n<p>A MedsBase 5 mg-os \u00e9s 10 mg-os liofiliz\u00e1lt palackokban k\u00edn\u00e1lja a KPV-t. Minden er\u0151ss\u00e9g el\u00e9rhet\u0151 10, 20 vagy 30 palackos csomagokban. Minden palack 99%+-os HPLC tisztas\u00e1g\u00fa, anal\u00edzisigazol\u00e1ssal rendelkezik k\u00e9r\u00e9sre.<\/p>\n<h3>KPV okoz-e mell\u00e9khat\u00e1sokat kutat\u00e1sban?<\/h3>\n<p>A k\u00f6zz\u00e9tett preklinikai kutat\u00e1sok jelent\u0151s biztons\u00e1gi profilt mutattak ki. Mivel a KPV-nek nincs melanokortin-receptor aktivit\u00e1sa, a pigment\u00e1ci\u00f3, az arousal \u00e9s a v\u00e9rnyom\u00e1sra gyakorolt hat\u00e1sok, amelyeket n\u00e9ha teljes MC agonist\u00e1kn\u00e1l figyelhet\u00fcnk meg, a KPV eset\u00e9n nem fordulnak el\u0151. Nem \u00e9szleltek jelent\u0151s off-target jeleket a tipikus kutat\u00e1si d\u00f3zisokn\u00e1l. Hossz\u00fa t\u00e1v\u00fa hum\u00e1n biztons\u00e1gi adatok nem \u00e1llnak rendelkez\u00e9sre.<\/p>\n<h3>Mi a KPV felez\u00e9si ideje?<\/h3>\n<p>A KPV (Liz-Pro-Val) egy tripeptid, amelynek r\u00f6vid plazmafelez\u00e9si ideje van, ami \u00f6sszhangban van a kis m\u00f3dos\u00edtatlan peptidekkel \u2013 becsl\u00e9sek szerint kevesebb, mint 30 perc. Els\u0151dleges kutat\u00e1si alkalmaz\u00e1sa a gasztrointesztin\u00e1lis ter\u00fcletre ir\u00e1nyul, ahol a lok\u00e1lis sz\u00e1ll\u00edt\u00e1si tanulm\u00e1nyok hat\u00e1sokat mutatnak a b\u00e9l epithel sejtekre \u00e9s az immunsejt-popul\u00e1ci\u00f3kra, amelyek a plazm\u00e1ban val\u00f3 \u00e9szlel\u00e9sen t\u00fal is fennmaradnak, ami a b\u00e9l ny\u00e1lkah\u00e1rty\u00e1j\u00e1n t\u00f6rt\u00e9n\u0151 k\u00f6zvetlen receptor k\u00f6lcs\u00f6nhat\u00e1snak tulajdon\u00edthat\u00f3.<\/p>\n<h3>Hogyan cs\u00f6kkenti a KPV a gyullad\u00e1st kutat\u00e1si modellekben?<\/h3>\n<p>A KPV az \u03b1-MSH (alfa-melanocit stimul\u00e1l\u00f3 hormon) C-termin\u00e1lis tripeptidje, \u00e9s megtartja a sz\u00fcl\u0151 peptid anti-inflammatorikus aktivit\u00e1s\u00e1nak nagy r\u00e9sz\u00e9t az MC1R aktiv\u00e1ci\u00f3 r\u00e9v\u00e9n. Colitis \u00e9s b\u00e9lk\u00e1rosod\u00e1si modellekben a KPV cs\u00f6kkenti az NF-\u03baB jelz\u00e9st, cs\u00f6kkenti a pro-inflammatorikus citokinek termel\u00e9s\u00e9t (IL-1\u03b2, IL-6, TNF-\u03b1), \u00e9s el\u0151seg\u00edti a b\u00e9l epithel barrier integrit\u00e1s\u00e1t. Kis m\u00e9rete lehet\u0151v\u00e9 teszi a k\u00f6zvetlen epithel sejt felv\u00e9telt, f\u00fcggetlen\u00fcl a hordoz\u00f3 feh\u00e9rj\u00e9kt\u0151l.<\/p>\n<h3>Rendelhetek KPV-t nemzetk\u00f6zi sz\u00e1ll\u00edt\u00e1sra?<\/h3>\n<p>Igen. A MedsBase vil\u00e1gszerte sz\u00e1ll\u00edt KPV-t a dedik\u00e1lt peptid sz\u00e1ll\u00edt\u00e1si h\u00e1l\u00f3zatunkon kereszt\u00fcl. A csak peptidet tartalmaz\u00f3 rendel\u00e9sek jogosultak az \u00f6n\u00e1ll\u00f3 peptid sz\u00e1ll\u00edt\u00e1si szolg\u00e1ltat\u00e1sunkra. A rendel\u00e9sek h\u0151m\u00e9rs\u00e9klet-kontroll\u00e1lt csomagol\u00e1sban ker\u00fclnek kisz\u00e1ll\u00edt\u00e1sra, teljes nyomon k\u00f6vet\u00e9ssel.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Egy\u00e9b peptidok a regener\u00e1ci\u00f3 \u00e9s teljes\u00edtm\u00e9ny kutat\u00e1s\u00e1hoz<\/h2>\n<ul>\n<li><a href=\"\/hu\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Testv\u00e9d\u0151 vegy\u00fclet \u2014 \u00edn, szalag, b\u00e9l regener\u00e1ci\u00f3s kutat\u00e1s<\/li>\n<li><a href=\"\/hu\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragmentum \u2014 l\u00e1gy sz\u00f6vetek \u00e9s \u00e9rrendszer regener\u00e1ci\u00f3s kutat\u00e1s<\/li>\n<li><a href=\"\/hu\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Szelekt\u00edv ghrelin agonist \u2014 tiszta GH impulzus kortizol\/prolaktin n\u00e9lk\u00fcl<\/li>\n<li><a href=\"\/hu\/cjc-1295-with-dac\/\"><strong>CJC-1295 DAC-val<\/strong><\/a> \u2014 GHRH anal\u00f3g meghosszabb\u00edtott felez\u00e9si id\u0151vel<\/li>\n<li><a href=\"\/hu\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 R\u00e9zpeptid \u2014 b\u0151r \u00e9s k\u00f6t\u0151sz\u00f6vet regener\u00e1ci\u00f3s kutat\u00e1s<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Tov\u00e1bbi olvasnival\u00f3<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Ismerd meg a peptid m\u00f6g\u00f6tt \u00e1ll\u00f3 kutat\u00e1st<\/strong><\/p>\n<p style=\"margin: 0;\">Olvasd el teljes, bizony\u00edt\u00e9kokon alapul\u00f3 \u00fatmutat\u00f3nkat: <a href=\"https:\/\/medsbase.com\/hu\/kpv-peptide-anti-inflammatory-guide\/\"><strong>KPV \u2014 a C-termin\u00e1lis alfa-MSH fragmentum gyullad\u00e1scs\u00f6kkent\u0151 kutat\u00e1sokhoz<\/strong><\/a>. Le\u00edrja az NFkB farmakol\u00f3gi\u00e1j\u00e1t, a masztsejtek stabiliz\u00e1l\u00e1s\u00e1t, az IBD kutat\u00e1st\u00f6rt\u00e9net\u00e9t, az or\u00e1lis \u00e9s subkut\u00e1n protokollokat, valamint a BPC-157-szel val\u00f3 kombin\u00e1l\u00e1s lehet\u0151s\u00e9geit.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 T\u00e1mogatja a sz\u00f6vetregener\u00e1ci\u00f3t<br \/>\n\u2705 Cs\u00f6kkenti az oxidat\u00edv stresszt<br \/>\n\u2705 Szab\u00e1lyozza az immunv\u00e1laszt<br \/>\n\u2705 Fokozza a sejtek ellen\u00e1ll\u00f3 k\u00e9pess\u00e9g\u00e9t<br \/>\n\u2705 Jav\u00edtja az epit\u00e9l integrit\u00e1s\u00e1t<\/p>\n<p><strong>KPV<\/strong> szintetikus peptidvegy\u00fcletet tartalmaz.<\/p>","protected":false},"featured_media":70964,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5472,5473],"class_list":{"0":"post-69013","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-kpv","8":"product_tag-lysine-proline-valine","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product\/69013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/comments?post=69013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media\/70964"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/media?parent=69013"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_brand?post=69013"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_cat?post=69013"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/hu\/wp-json\/wp\/v2\/product_tag?post=69013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}